The loss of CARA Therapeutics under GAAP for 6 months of 2020 amounted to $53.99 million, an increase of 20.2% compared to $44.92 million in the previous year. Revenues increased by 43.1% to $13,727 million from $9.59 million a year earlier.
The loss of CARA Therapeutics under GAAP for 6 months of 2020 amounted to $53.99 million, an increase of 20.2% compared to $44.92 million in the previous year. Revenues increased by 43.1% to $13,727 million from $9.59 million a year earlier. 
ir.caratherapeutics.com
English (US) 